share_log

Canaccord Genuity Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $109

Benzinga ·  May 6 13:35

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $111 to $109.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment